Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy

References

• Kakar P, Lip GY. Towards understanding the aetiology and pathophysiology of human hypertension: where are we now? J. Hum. Hypertens.20, 833–836 (2006).
   PubMed Web of Science ®Google Scholar
• Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr. Pharm. Des.12, 1623–1635 (2006).
   PubMed Web of Science ®Google Scholar
• Boos CJ, Lip GY. Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension? J. Hum. Hypertens.19, 511–513 (2005).
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Rifai N Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA290, 2945–2951 (2003).
   PubMed Web of Science ®Google Scholar
• Galle J, Quaschning T, Seibold S, Wanner C. Endothelial dysfunction and inflammation: what is the link? Kidney Int. Suppl.84, S45–S49 (2003).
   Google Scholar
• Clapp BR, Hingorani AD, Kharbanda RK et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc. Res.64, 172–178 (2004).
   PubMed Web of Science ®Google Scholar
• Lip GY, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J. Hum. Hypertens.8, 693–702 (1994).
   PubMed Web of Science ®Google Scholar
• Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J. Cardiovasc. Pharmacol.38, S3–S6 (2001).
   PubMedGoogle Scholar
• Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation105, 546–549 (2002).
   PubMed Web of Science ®Google Scholar
• Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis.38, 87–104 (1995).
   PubMed Web of Science ®Google Scholar
• Jones CJH, Kuo L, Davis MJ, deFily DV, Chillian WM. Role of nitric oxide in coronary microvascular responses to adenosine and increased metabolic demand. Circulation91, 1807–1813 (1996).
   Web of Science ®Google Scholar
• Cooke JP, Tsao PS. Go with the flow. Circulation103, 2773–2775 (2001).
   PubMed Web of Science ®Google Scholar
• Miura H, Watchel RE, Liu Y et al. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. Circulation103, 1992–1998 (2001).
   PubMed Web of Science ®Google Scholar
• Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerosis coronary arteries. N. Engl. J. Med.315, 1046–1051 (1986).
   PubMed Web of Science ®Google Scholar
• Huang PL, Huang Z, Mashimo H et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature377, 239–242 (1995).
   PubMed Web of Science ®Google Scholar
• Suda O, Tsutsui M, Morishita T et al. Long-term treatment with N(ω)-nitro- L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation106, 1729–1735 (2002).
   PubMed Web of Science ®Google Scholar
• Hyndman ME, Parsons HG, Verma S et al. The T-786→C mutation in endothelial nitric oxide synthase is associated with hypertension. Hypertension39, 919–922 (2002).
   PubMed Web of Science ®Google Scholar
• Lacolley P, Gautier S, Poirier O, Pannier B, Cambien F, Benetos A. Nitric oxide synthase gene polymorphisms, blood pressure and aortic stiffness in normotensive and hypertensive subjects. J. Hypertens.16, 31–35 (1998).
   PubMed Web of Science ®Google Scholar
• Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc. Natl Acad. Sci. USA93, 9114–9119 (1996).
   PubMed Web of Science ®Google Scholar
• Beghetti M, Sparling C, Cox PN, Stephens D, Adatia I. Inhaled NO inhibits platelet aggregation and elevates plasma but not intraplatelet cGMP in healthy human volunteers. Am. J. Physiol. Heart Circ. Physiol.285, H637–H642 (2003).
   Google Scholar
• Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA88, 4651–4655 (1991).
   PubMed Web of Science ®Google Scholar
• Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ. Res.76, 980–986 (1995).
   PubMed Web of Science ®Google Scholar
• Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation106, 1439–1441 (2002).
   PubMed Web of Science ®Google Scholar
• Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation106, 913–919 (2002).
   PubMed Web of Science ®Google Scholar
• Nickening G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. Circulation105, 393–396 (2002).
   PubMed Web of Science ®Google Scholar
• Landmesser U, Harrison DG. Oxidant stress and marker for cardiovascular events. Ox marks the spots. Circulation104, 2638–2640 (2001).
   PubMed Web of Science ®Google Scholar
• Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I: basic mechanisms and in vivo monitoring of ROS. Circulation108, 1912–1916 (2003).
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature420, 868–874 (2002).
   PubMed Web of Science ®Google Scholar
• Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension38, 606–611 (2001).
   PubMed Web of Science ®Google Scholar
• Böger R, Bode-Böger S, Szuba A et al. Asymetric Dimethylarginina (ADMA). A novel risk factor for endothelial dysfunction. Circulation98, 1842–1847 (1998).
   PubMed Web of Science ®Google Scholar
• Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int.59, 1466–1472 (2001).
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet339, 572–575 (1992).
   PubMed Web of Science ®Google Scholar
• Griendling KK, Minieri CA, Ollerenshaw JD et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. Circ. Res.74, 1141–1148 (1994).
   PubMed Web of Science ®Google Scholar
• Harrison DG. Endothelial function and oxidant stress. Clin. Cardiol.20(Suppl. II), 11–17 (1997).
   PubMed Web of Science ®Google Scholar
• Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation101, 1372–1378 (2000).
   PubMed Web of Science ®Google Scholar
• Lemay J, Hamet P, deBlois D. Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury. J. Renin Angiotensin Aldosterone Syst.1, 46–50 (2000).
   PubMedGoogle Scholar
• Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv. Exp. Med. Biol.432, 35–44 (1997).
   PubMed Web of Science ®Google Scholar
• Ohkita M, Takaoka M, Shiota Y, Nojiri R, Matsumura Y. Nitric oxide inhibits endothelin-1 production through the suppression of nuclear factor κ B. Clin. Sci. (Lond.)103(Suppl. 48), 68S–71S (2002).
   Google Scholar
• Li J, Zhao SP, Li XP, Zhuo QC, Gao M, Lu SK. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. Int. J. Cardiol.61, 165–169 (1997).
   PubMed Web of Science ®Google Scholar
• Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J. Hypertens.19, 415–420 (2001).
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation101, 1653–1659 (2000).
   PubMed Web of Science ®Google Scholar
• Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J. Hypertens.19, 921–930 (2001).
   PubMed Web of Science ®Google Scholar
• Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med.323, 22–27 (1990).
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Mattei P, Salvetti A. Defective L-arginine–nitric oxide pathway in offspring of essential hypertensive patients. Circulation94, 1298–1303 (1996).
   PubMed Web of Science ®Google Scholar
• Lee AJ. The role of rheology and hemostatic factors in hypertension. J. Hum. Hypertens.11, 767–776 (1997).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J. Hum. Hypertens.8, 693–701 (1994).
   PubMed Web of Science ®Google Scholar
• Lip GY, Blann AD, Edmunds E, Beevers DG. Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagul. Fibrinolysis13, 35–41 (2002).
   PubMed Web of Science ®Google Scholar
• Agewall S, Wikstrand J, Fagerberg B. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. J. Hypertens.16, 537–541 (1998).
   PubMed Web of Science ®Google Scholar
• Poli KA, Tofler GH, Larson MG et al. Association between blood pressure and fibrinolytic potential in the Framingham Offspring population. Circulation101, 264–269 (2000).
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan RT. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur. Heart J.14, 597–601 (1993).
   PubMed Web of Science ®Google Scholar
• Smith WCS, Lowe GDO, Lee AJ, Tunstall-Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J. Hypertens.10, 467–472 (1992).
   PubMed Web of Science ®Google Scholar
• Spencer CG, Martin SC, Felmeden DC, Blann AD, Beevers GD, Lip GY. Relationship of homocysteine to markers of platelet and endothelial activation in “high risk” hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Int. J. Cardiol.94, 293–300 (2004).
   PubMed Web of Science ®Google Scholar
• Memeh CU. The relationship between body weight and plasma viscosity in hypertensive diabetic Nigerians. J. Hypertens.8, 711–714 (1990).
   PubMed Web of Science ®Google Scholar
• Lip GY, Blann AD, Beevers DG. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic–diastolic hypertension. J. Hypertens.17, 1203–1207 (1999).
   PubMed Web of Science ®Google Scholar
• Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG. Relationship of endothelium, thrombogenesis, and haemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am. J. Cardiol.80, 1566–1571 (1997).
   PubMed Web of Science ®Google Scholar
• Blann AD, Waite MA. Von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron. Artery Dis.7, 143–147 (1996).
   PubMed Web of Science ®Google Scholar
• Kloczko J, Wojukiewicz MZ, Bielawiec M, Galar M, Tarasow E. Von Willebrand factor antigen and fibronectin in essential hypertension. Thromb. Res.79, 331–336 (1995).
   PubMed Web of Science ®Google Scholar
• Stone MC, Thorp JM. Plasma fibrinogen: a major coronary risk factor. J. Roy. Coll. Gen. Prac.35, 565–569 (1985).
   PubMedGoogle Scholar
• Spencer CG, Gurney D, Felmeden DC, Blann AD, Beevers DG, Lip GY. Platelet and haemorheological markers in ‘high risk’ hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J. Intern. Med.255, 59–56 (2004).
   PubMed Web of Science ®Google Scholar
• Lee KW, Blann AD, Lip GY. High pulse pressure and nondipping circadian blood pressure in patients withcoronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am. J. Hypertens.18, 104–115 (2005).
   PubMed Web of Science ®Google Scholar
• Pedrinelli R, Giampetro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction inessential hypertension. Lancet344, 14–18 (1994).
   PubMed Web of Science ®Google Scholar
• Sechi LA, Zingaro L, Catena C, Casaccio D, De Mrchi S. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension36, 978–985 (2000).
   PubMed Web of Science ®Google Scholar
• Spencer CGC, Gurney D, Blann AD, Beevers DG, Lip GYH. Are plasma markers of platelet, endothelial and hemostatic function related to conventional measures of cardiovascular risk in hypertensives? Am. J. Hypertens.13, 237A (2000).
   Google Scholar
• Pober JS. Cytokine mediated activation of vascular endothelium. Am. J. Pathol.133, 426–433 (1988).
   PubMed Web of Science ®Google Scholar
• March F, Schoembeck U, Bonnefoy JY. Activation of the monocyte/macrophage related to acute atheroma complication by ligation of CD-40 induction of collagenase, stromelysin, and tissue factor. Circulation96, 396–399 (1997).
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Grafe M. CD-40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature391, 591–594 (1998).
   PubMed Web of Science ®Google Scholar
• von Hundelshausen P, Weber KSC, Huo Y. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation103, 1772–1777 (2001).
   PubMed Web of Science ®Google Scholar
• Yeh ETH, Anderson V, Pasceri V, Willerson JT. C-Reactive Protein. Linking inflammation to cardiovascular complications. Circulation104, 974–975 (2001).
   PubMed Web of Science ®Google Scholar
• Podhaisky HP Abate A, Polte T, Oberle S, Schroder H. Aspirin protects endothelial cells from oxidative stress – possible synergism with vitamin E. FEBS Lett.417, 349–351 (1997).
   PubMed Web of Science ®Google Scholar
• Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart77, 333–337 (1997).
   PubMed Web of Science ®Google Scholar
• Kharbanda RK Walton B, Allen M et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation105, 2600–2604 (2002).
   PubMed Web of Science ®Google Scholar
• Husain S Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation97, 716–720 (1998).
   PubMed Web of Science ®Google Scholar
• Grosser N, Schroder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler. Thromb. Vasc. Biol.23, 1345–1351 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J. Hum. Hypertens.19, 185–196 (2005).
   PubMed Web of Science ®Google Scholar
• Thrombosis prevention trial: randomised trial of low-intensity oralanticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet24, 233–241 (1998).
   Google Scholar
• Huynh T, Theroux P, Bogaty P et al. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation103, 3069–3074 (2001).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J.324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines committee. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al.; and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Kakar P, Lip GYH. Towards improving the clinical assessment and management of human hypertension: an overview from this journal. J. Hum. Hypertens.20(12), 913–916 (2006).
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace8, 651–745 (2006).
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Capucci A, Lip GYH et al; on behalf of the Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur. Heart J.27, 3018–3026 (2006).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur. Heart J.28(6), 752–759 (2007).
   PubMed Web of Science ®Google Scholar
• Brewster L, van Montfrans G, Kleijnen J. Implications of the final results of LIFE, AASK and ALLHAT for antihypertensive treatment in black people. A Cochrane systematic review. J. Hypertens.21(Suppl. 4), S120 (2003).
   Google Scholar
• Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann. Pharmacother.41(3), 456–464 (2007).
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet348, 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar